KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Finished Goods: 2011-2024

Historic Finished Goods for Halozyme Therapeutics (HALO) over the last 14 years, with Dec 2024 value amounting to $142.9 million.

  • Halozyme Therapeutics' Finished Goods rose 12.59% to $161.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.6 million, marking a year-over-year increase of 12.59%. This contributed to the annual value of $142.9 million for FY2024, which is 104.41% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Finished Goods of $142.9 million as of FY2024, which was up 104.41% from $69.9 million recorded in FY2023.
  • Halozyme Therapeutics' Finished Goods' 5-year high stood at $142.9 million during FY2024, with a 5-year trough of $21.2 million in FY2020.
  • Its 3-year average for Finished Goods is $86.3 million, with a median of $69.9 million in 2023.
  • Data for Halozyme Therapeutics' Finished Goods shows a peak YoY spiked of 104.41% (in 2024) over the last 5 years.
  • Over the past 5 years, Halozyme Therapeutics' Finished Goods (Yearly) stood at $21.2 million in 2020, then increased by 21.65% to $25.8 million in 2021, then surged by 78.28% to $46.0 million in 2022, then spiked by 52.12% to $69.9 million in 2023, then skyrocketed by 104.41% to $142.9 million in 2024.